New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) --…
With significant clinical results published in the Nature Medicine Journal, InBrain Pharma is about to durably modify the advanced Parkinson’s disease management
A World Premiere in Parkinson’s Disease With significant clinical results published in…
Tech Mahindra and Wall Street Journal Intelligence Launch ‘The Tech Adoption Index’ Report at WEF 2025
DAVOS, Switzerland, Jan. 23, 2025 /PRNewswire/ -- Tech Mahindra (NSE: TECHM), a leading…
Tech Mahindra and Wall Street Journal Intelligence Launch ‘The Tech Adoption Index’ Report at WEF 2025
DAVOS, Switzerland, Jan. 23, 2025 /PRNewswire/ -- Tech Mahindra (NSE: TECHM), a leading…
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atr
January 22, 2025 17:00 ET | Source: Anthos Therapeutics Secondary endpoints also…
Myriad Genetics RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.…
Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle
December 13, 2024 03:00 ET | Source: Actimed Therapeutics London, UK –…
COVID Vaccines Genetic Mechanism Inadequately Tested, according to Journal of American Physicians and Surgeons (AAPS)
TUCSON, Ariz., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The regulatory framework has…
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
November 20, 2024 16:30 ET | Source: Sirona Biochem Corp. VANCOUVER, British…
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
November 14, 2024 07:01 ET | Source: Invivyd The New England Journal…